NLS Pharmaceutics (NLSP)
(Delayed Data from NSDQ)
$2.14 USD
+0.12 (5.94%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $2.13 -0.01 (-0.47%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NLSP 2.14 +0.12(5.94%)
Will NLSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NLSP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NLSP
NLS Pharmaceutics (NLSP) Gains BIRD Foundation Support for Diabetes Therapy | NLSP Stock News
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation ...
NLS Pharmaceutics merger partner Kadimastem wins milestone payment
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing | ...